Display options
Cite
Ashton AK, Jamerson BD, L Weinstein W, et al. Antidepressant-related adverse effects impacting treatment compliance: Results of a patient survey. Curr Ther Res Clin Exp. 2005;66(2):96-106doi: 10.1016/j.curtheres.2005.04.006.
Ashton, A. K., Jamerson, B. D., L Weinstein, W., & Wagoner, C. (2005). Antidepressant-related adverse effects impacting treatment compliance: Results of a patient survey. Current therapeutic research, clinical and experimental, 66(2), 96-106. https://doi.org/10.1016/j.curtheres.2005.04.006
Ashton, Adam Keller, et al. "Antidepressant-related adverse effects impacting treatment compliance: Results of a patient survey." Current therapeutic research, clinical and experimental vol. 66,2 (2005): 96-106. doi: https://doi.org/10.1016/j.curtheres.2005.04.006
Ashton AK, Jamerson BD, L Weinstein W, Wagoner C. Antidepressant-related adverse effects impacting treatment compliance: Results of a patient survey. Curr Ther Res Clin Exp. 2005 Mar;66(2):96-106. doi: 10.1016/j.curtheres.2005.04.006. PMID: 24672116; PMCID: PMC3964563.
Copy Download .nbib Format: NLM
Share it on

Curr Ther Res Clin Exp. 2005 Mar;66(2):96-106. doi: 10.1016/j.curtheres.2005.04.006.

Antidepressant-related adverse effects impacting treatment compliance: Results of a patient survey.

Current therapeutic research, clinical and experimental

Adam Keller Ashton, Brenda D Jamerson, Wendy L Weinstein, Christine Wagoner

Affiliations

  1. Department of Psychiatry, State University of New York at Buffalo, School of Medicine and Biomedical Sciences, Williamsville, New York, USA.
  2. Department of Clinical Research, Campbell University, Morrisville, North Carolina, USA.
  3. Department ofMarket Research, GlaxoSmithKline, Research Triangle Park, North Carolina, USA.

PMID: 24672116 PMCID: PMC3964563 DOI: 10.1016/j.curtheres.2005.04.006

Abstract

BACKGROUND: Despite the high prevalence of depression in the United States, 10 few studies have identified which adverse effects (AEs) patients are willing or unwilling to tolerate when receiving antidepressants.

OBJECTIVE: The aim of this study was to identify reasons for discontinuation10 and noncompliance with antidepressant medications, the impact of AEs on compliance and quality of life (assessed using impact of AEs on activities of daily living), and patients' suggestions for improving their medication, using a patient survey.

METHODS: Patients aged 18 to 65 years with mild to severe depression were 10 randomly selected by their physicians to be sent an invitation to complete the 42-question survey. Three hundred physicians nationwide assessed the severity of depression and symptoms of anxiety in each respondent, using their judgment. Patients were asked specific questions to assess reasons for discontinuation/noncompliance. Patients were also asked to rate AEs based on how difficult they were to "live with," and what 2 aspects of their antidepressant medication they would change if they could.

RESULTS: In a separate, concurrent study, physicians classified 175 (50%) abdResults:0 mildly to moderately depressed and 84 (24%) as severely depressed. Ninety-one respondents (26%) were classified as having symptoms of anxiety. Two hundred seven patients (60%) indicated they had discontinued treatment with an antidepressant agent at some point in their lives, the most common reason for which was lack of efficacy (92 patients [44%]). Of the 344 patients currently being treated with an antidepressant, 75 (22%) reported noncompliance. The most common reasons for noncompliance were "have trouble remembering to take it" (19/44 patients [43%]), "gained a lot of weight" (11/41 [27%]), "unable to have an orgasm" (8/40 [20%]), and "lost interest in sex" (8/41 [20%]). The 4 AEs patients expressed as "extremely difficult to live with" were "weight gain" (104 patients [31%]), "unable to have erection" (83 [25%]), "difficulty reaching orgasm" (80 [24%]), and "tired during the day/no energy" (69 patients [21%]). The 3 most frequently cited improvements patients (n = 327) would make to their medications were better efficacy (176 patients [54%]) and eliminating AEs related to sexual desire and weight gain (112 [34%] and 105 [32%] patients, respectively).

CONCLUSIONS: The findings of this survey of patients with mild to severe10 depression suggest that compliance, and hence efficacy, can be promoted by (1) understanding what patients expect and desire from the antidepressants they are prescribed and (2) prescribing antidepressants associated with low rates of weight gain, sexual dysfunction, or tiredness.

Keywords: antidepressants; discontinuation; noncompliance; tolerability

References

  1. Patient Educ Couns. 2000 May;40(2):173-85 - PubMed
  2. Psychiatr Serv. 1998 Feb;49(2):196-201 - PubMed
  3. Clin Ther. 2001 Aug;23(8):1296-310 - PubMed
  4. Biol Psychiatry. 2002 May 1;51(9):753-61 - PubMed
  5. Int J Psychiatry Clin Pract. 2001;5(1):29-35 - PubMed
  6. J Clin Psychiatry. 2000;61 Suppl 2:6-9 - PubMed
  7. J Clin Psychiatry. 2001;62 Suppl 22:30-3 - PubMed
  8. Depress Anxiety. 2001;13(1):1-10 - PubMed
  9. Natl Vital Stat Rep. 2000 Jul 24;48(11):1-105 - PubMed
  10. J Sex Marital Ther. 1998 Jul-Sep;24(3):191-2 - PubMed
  11. Med Care Res Rev. 2000 Dec;57(4):491-512 - PubMed
  12. Contemp Pharm Pract. 1981 Winter;4(1):8-11 - PubMed
  13. J Clin Psychiatry. 1997;58 Suppl 1:11-4 - PubMed
  14. Am J Manag Care. 2000 Feb;6(2 Suppl):S31-8 - PubMed
  15. Acta Psychiatr Scand. 2002 Mar;105(3):164-72 - PubMed
  16. J Clin Psychiatry. 2000;61 Suppl 2:20-5 - PubMed
  17. J Clin Psychiatry. 2000 Nov;61(11):863-7 - PubMed
  18. Ann Pharmacother. 2002 Apr;36(4):578-84 - PubMed
  19. J Clin Psychiatry. 1993 Nov;54(11):405-18 - PubMed

Publication Types